MLMiranda A. Lewis

Miranda A. Lewis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miranda A. Lewis has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Frederick H. Neill

    Department of Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas, USA

    1 shared publication
  • Gurpreet Kaur

    Department of Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas, USA

    1 shared publication
  • Ketki Patil

    Department of Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas, USA

    1 shared publication
  • Khalil Ettayebi

    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA

    1 shared publication
  • Mary K. Estes

    Department of Molecular Virology and Microbiology, Baylor College of Medicine

    1 shared publication
  • Nicolás W. Cortés-Penfield

    Department of Medicine, Infectious Diseases, University of Nebraska Medical Center , Omaha, Nebraska, USA

    1 shared publication

Latest Publications

  • Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity

    by Miranda A. Lewis, Nicolás W. Cortés-Penfield, Khalil Ettayebi, Ketki Patil, Gurpreet Kaur, Frederick H. Neill, Robert L. Atmar, Sasirekha Ramani, Mary K. Estes

    Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis. In immunocompetent hosts, symptoms usually resolve within 3 days; however, in immunocompromised persons, HuNoV infection can become persistent, debilitating, and sometimes life-threatening. There are no licensed therapeutics for HuNoV due to a near half-century delay in its cultivation. Treatment for chronic HuNoV infection in immunosuppressed patients anecdotally includes nitazoxanide, a broad-spectrum antimicrobial licensed for treatment of parasite-induced gastroenteritis. Despite its off-label use for chronic HuNoV infection, nitazoxanide has not been clearly demonstrated to be an effective treatment. In this study, we standardized a pipeline for antiviral testing using multiple human small intestinal enteroid lines representing different intestinal segments and evaluated whether nitazoxanide inhibits replication of five HuNoV strains in vitro . Nitazoxanide did not exhibit high selective antiviral activity against any HuNoV strain tested, indicating it is not an effective antiviral for HuNoV infection. Human intestinal enteroids are further demonstrated as a model to serve as a preclinical platform to test antivirals against HuNoVs to treat gastrointestinal disease. Abstr